Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cristina Martínez-Toledo
Observed names:
C. Martínez-Toledo,
Cristina Martinez-Toledo,
Cristina Mártinez-Toledo,
Martínez-Toledo, Cristina
Institutions:
Hospital Universitario Puerta de Hierro Majadahonda,
Universidad Autónoma de Madrid
Observed institutions:
Hospital Universitario Puerta de Hierro Majadahonda,
Comunidad de Madrid,
Universidad Autónoma de Madrid
ORCID:
0000-0002-0663-0674
Observed ORCID:
0000-0002-0663-0674
OpenAlex ID:
A5063740705
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
2024
·
Mariano Provencio
, Ernest Nadal
, et al.
·
The Lancet Oncology
·
124
PDF
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
2022
·
Marta Casarrubios
, Mariano Provencio
, et al.
·
Journal for ImmunoTherapy of Cancer
·
77
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
2022
·
Mariano Provencio
, Ana Laura Ortega
, et al.
·
JAMA Oncology
·
56
PDF
OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
2024
·
M. Provencio
, B. Campos
, et al.
·
Journal of Thoracic Oncology
·
25
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
2024
·
Marta Molina-Alejandre
, Francisco Perea
, et al.
·
Journal for ImmunoTherapy of Cancer
·
22
PDF
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
2025
·
Mariano Provencio
, Begoña Campos
, et al.
·
Nature Communications
·
20
PDF
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
2025
·
Belén Sierra Rodero
, Cristina Martínez-Toledo
, et al.
·
OncoImmunology
·
10
PDF
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
·
Clinical Cancer Research
·
8
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
2025
·
María de Los Ángeles Gil González
, Marta Molina-Alejandre
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)
2023
·
B. Sierra-Rodero
, C. Martínez-Toledo
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer
2026
·
Marta Molina-Alejandre
, Cristina Martínez-Toledo
, et al.
·
Biomarker Research
·
1
PDF
Figure S9 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S1 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S4 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S6 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Table S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Table S11 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S8 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S2 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S10 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Table S4 and S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Table S6 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Data from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Table S12 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Figure S5 from Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer
2026
·
Belén Sierra-Rodero
, Ángeles Gil-González
, et al.
Show more works
View as search
Works count:
40
Citation count:
348
H-index:
8
I10-index:
7
Year
Topic
Type